Has Adam Salisbury, MD received payments from drug or device companies?

Yes. Drug and device makers reported $52,249 in general payments to Adam Salisbury, MD across 139 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Adam Salisbury, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Adam Salisbury, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Adam Salisbury, MD

Interventional Cardiology · Kansas City, MONPI 1861511081

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $45,310 of the $52,249 with a category attached, or 86.7%. Medtronic accounts for 73.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $23,908 and has fallen 95.6% since, to $1,062 in 2025.

$52,249in general payments, 2019–2025

Across 139 payments — averaging $375.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$38K
Abiomed$11K
Abbott$839
Boston Scientific$789
Shockwave Medical, Inc$751
Asahi Intecc USA, Inc.$409
plus $326 from 4 others

$213,174in research payments, 2019–2025

Across 37 payments — averaging $5761.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Siemens Medical Solutions USA, Inc.$97K
Medtronic$70K
Abbott$26K
Gilead$20K

What the payments were for

Consulting fees$4691%
Speaking & faculty fees$45,31087%
Travel & lodging$2671%
Food & beverage$6,20312%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	74	$38,383
Abiomed	6	$10,753
Abbott	26	$839
Boston Scientific	11	$789
Shockwave Medical, Inc	8	$751
Asahi Intecc USA, Inc.	3	$409
Organogenesis Inc.	1	$120
Penumbra, Inc.	7	$112
Angiodynamics, Inc.	2	$79
Stryker	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RESOLUTE ONYX$20,050
Resolute$11,859
Impella$10,548
Launcher$1,563
Export$938
ASAHI PTCA Guide Wire$409
Xience Alpine cornary stent system$309
ONYX FRONTIER$261
AVVIGO Guidance System$249
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$194
Xience V coronary stent system$162
OPTICROSS$143
Telescope$141
Rotablator Rotational Atherectomy System Console Kit$120
SYNERGY$120
Apligraf$120
OPTIS$105

How this compares

$52,249 in reported general payments places this provider in the 85th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri →

Medicare billing

Part B allowed, 2024

$120,347

Medicare patients

476

Services billed

1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	64	$67,061
JardianceEmpagliflozin	25	$32,711
Praluent PenAlirocumab	37	$28,901
XareltoRivaroxaban	23	$27,152
Repatha SureclickEvolocumab	17	$14,160
Repatha SyringeEvolocumab	12	$6,627
Ranolazine ErRanolazine	30	$2,927
Diltiazem 24hr Er (Cd)Diltiazem Hcl	36	$2,003
Rosuvastatin Calcium	112	$1,725
Metoprolol Succinate	135	$1,620
Atorvastatin Calcium	115	$1,036
Carvedilol	123	$1,009
ClopidogrelClopidogrel Bisulfate	99	$937
Ezetimibe	26	$928
Losartan Potassium	89	$681

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Kansas City

Gerald MancusoKansas City$402K
James GranthamKansas City$357K
Matthew BunteKansas City$242K
Adnan ChhatriwallaKansas City$114K
Kenneth HuberKansas City$110K
Chetan HudedKansas City$61K
Steven MarsoKansas City$42K
Dany JacobKansas City$35K
Muhammad Anis HaiderKansas City$35K
Francisco LammogliaKansas City$22K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →